Tasly Pharmaceutical Group Co Ltd
SSE:600535
Tasly Pharmaceutical Group Co Ltd
Revenue
Tasly Pharmaceutical Group Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tasly Pharmaceutical Group Co Ltd
SSE:600535
|
Revenue
¥8.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-4%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥12.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
¥10.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥28B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
¥40B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Revenue
¥2.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Tasly Pharmaceutical Group Co Ltd
Glance View
In the heart of China's bustling pharmaceutical landscape lies Tasly Pharmaceutical Group Co Ltd, a company intricately blending traditional herbal wisdom with cutting-edge scientific innovation. Founded in 1994, this enterprise has carved a niche in the competitive world of healthcare by focusing on Traditional Chinese Medicine (TCM) while also expanding into chemical medicine and biological drugs. Tasly's ecosystem thrives on the research, development, manufacturing, and marketing of its diverse product portfolio, which includes patent medicines, herbal injections, and health supplements. The crown jewel in its product lineup is the Compound Danshen Dripping Pill, a herbal medicine aimed at cardiovascular ailments, a testament to the company's commitment to merging ancient remedies with modern health solutions. By establishing an extensive distribution network both domestically and internationally, Tasly ensures its unique offerings reach a wide audience, catering not only to China's growing appetite for health products but also tapping into global markets hungry for alternative medicine solutions. Tasly’s financial engine leverages its broad spectrum of offerings, driven by both consumer demand for TCM and the pharmaceutical industry's appetite for innovation. The company invests significantly in research and development, with a particular emphasis on internationalizing TCM and obtaining global recognition for its products through clinical trials and partnerships. Such strategic actions bolster its competitive edge, positioning Tasly as a leader in an industry where tradition and science converge. Revenue streams are further diversified by the company's health management services and a growing footprint in biotechnology, showcasing its adaptability and forward-thinking approach. This intricate ballet of innovation and tradition enables Tasly Pharmaceutical Group to not just survive but thrive in an industry characterized by rapid advancements and shifting consumer paradigms.
See Also
What is Tasly Pharmaceutical Group Co Ltd's Revenue?
Revenue
8.6B
CNY
Based on the financial report for Sep 30, 2024, Tasly Pharmaceutical Group Co Ltd's Revenue amounts to 8.6B CNY.
What is Tasly Pharmaceutical Group Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
-4%
Over the last year, the Revenue growth was -6%. The average annual Revenue growth rates for Tasly Pharmaceutical Group Co Ltd have been 2% over the past three years , -15% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet